Welcome to Norganoid
Enhancing new Organ technology
We anticipate a future where preclinical experiments are conducted with unparalleled precision and efficiency, powered by automation and scalability.
Our mission is to develop preclinical models that mirror the clinical realities of diseases ensuring accuracy, reliability, and patient relevance.
Disrupting Drug Development
Unlocking the Potential of Human Organoid Testing
Our Lab Certification
We Live
in a Patient-centric Disease Model World
Challenges
Limitations of 2D Cell Cultures
2D cell cultures lack the ability to replicate the complex tissue organization found in the human body. Despite using human cells, traditional cell cultures fall short due to the absence of hierarchical structure, cellular diversity, and interactions between cells and their environment. This limitation prevents cell lines from accurately mimicking the functions present in real tissues, making the results from 2D cultures less predictive of clinical outcomes.
Reliability In Organoid Culture
Organoid culture is a complex and time-consuming process, with many protocols involving numerous manual steps that increase the risk of failure. Regulatory bodies demand robust and reproducible data from preclinical experiments to approve first-in-human trials. Relying on traditional cultivation methods is likely to continue resulting in setbacks and inefficiencies.
Limitations Of New Approach Methodologies
While liquid-handling robots can automate manual steps, their use in 3D cell culture results in high consumable costs and significant variability in organoid production. Organ-on-a-Chip (OoC) technology increases in vitro model complexity but suffers from low experimental throughput and is typically restricted to modeling a single organ. In silico methods offer the fastest and most cost-effective predictions, but they are limited in effectiveness when not combined with other New Approach Methodologies (NAMs).
Our Solutions
Advancing Preclinical Experiments
we overcome the limitations of traditional 2D cell cultures by accurately replicating the complex architecture and cellular interactions found in real tissues. Unlike flat, two-dimensional models, organoids provide a dynamic environment where cells can organize, differentiate, and interact in ways that closely mirror actual human organs. This enables organoid-based studies to yield data that is far more predictive of how treatments will perform in clinical settings.
Revolutionizing OOC Technology
Our (NLS™) is crafted to provide a plug-and-play organ-on-chip (OoC) platform. It manages the full spectrum of processes, from the initial differentiation of induced pluripotent stem cells (iPSC) to the intricate culture and ongoing maintenance of organoids. Designed for robust compatibility, NLS™ effortlessly integrates with standard imaging systems, enhancing both functionality and efficiency in laboratory settings.
AI-Driven Drug Safety Screening
By integrating automated organ-on-chip (OoC) technology with advanced computer vision, we aim to dramatically enhance the predictive accuracy of drug and chemical safety screenings. Our goal is to broaden the use of organoids and propel the pharmaceutical and biotechnology industries into a new era of patient-centric preclinical experiments. This approach not only improves outcomes but also aligns with the evolving demands of healthcare research.
Why People Trust Us
High Quality Lab
Unmatched Expertise
Precise Result
Qualified Staff
Our CEO & Founder
.
